DXC Technology Company (DXC)

Theseus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	12,794	12,871	13,667	14,430	16,265	17,729
Revenue Growth (YoY)	-4.93%	-5.82%	-5.29%	-11.28%	-8.26%	-9.44%
Cost of Revenue	9,632	9,770	10,576	11,246	12,683	14,086
Gross Profit	3,162	3,101	3,091	3,184	3,582	3,643
Selling, General & Admin	1,022	929	1,521	2,456	316	1,818
Operating Expenses	2,287	2,216	2,925	3,975	2,033	3,623
Operating Income	875	885	166	-791	1,549	20
Interest Expense	-247	-265	-298	-200	-204	-361
Interest & Investment Income	194	199	214	135	65	98
Currency Exchange Gain (Loss)	4	4	7	15	-13	-14
Other Non Operating Income (Expenses)	-3	3	68	60	-60	7
EBT Excluding Unusual Items	823	826	157	-781	1,337	-250
Merger & Restructuring Charges	-151	-153	-111	-216	-318	-551
Gain (Loss) on Sale of Investments	-	-	-	-	-	15
Gain (Loss) on Sale of Assets	-16	-16	86	211	459	2,004
Asset Writedown	-	-	-	-	-	-165
Legal Settlements	-2	-2	-16	-75	-	-
Other Unusual Items	-25	-25	-7	-24	-337	-399
Pretax Income	629	630	109	-885	1,141	654
Income Tax Expense	240	234	23	-319	405	800
Earnings From Continuing Operations	389	396	86	-566	736	-146
Net Income to Company	389	396	86	-566	736	-146
Minority Interest in Earnings	-10	-7	5	-2	-18	-3
Net Income	379	389	91	-568	718	-149
Net Income to Common	379	389	91	-568	718	-149
Net Income Growth	367.90%	327.47%	-	-	-	-
Shares Outstanding (Basic)	181	181	196	229	250	254
Shares Outstanding (Diluted)	185	185	199	229	255	254
Shares Change (YoY)	-2.96%	-6.97%	-13.19%	-10.27%	0.42%	-1.71%
EPS (Basic)	2.09	2.15	0.46	-2.48	2.87	-0.59
EPS (Diluted)	2.05	2.10	0.46	-2.48	2.81	-0.59
EPS Growth	384.35%	356.52%	-	-	-	-
Free Cash Flow	1,103	1,150	1,179	1,148	1,247	-137
Free Cash Flow Per Share	5.95	6.22	5.93	5.01	4.89	-0.54
Gross Margin	24.71%	24.09%	22.62%	22.07%	22.02%	20.55%
Operating Margin	6.84%	6.88%	1.21%	-5.48%	9.52%	0.11%
Profit Margin	2.96%	3.02%	0.67%	-3.94%	4.41%	-0.84%
Free Cash Flow Margin	8.62%	8.94%	8.63%	7.96%	7.67%	-0.77%
EBITDA	1,959	1,993	1,387	556	3,064	1,744
EBITDA Margin	15.31%	15.48%	10.15%	3.85%	18.84%	9.84%
D&A For EBITDA	1,084	1,108	1,221	1,347	1,515	1,724
EBIT	875	885	166	-791	1,549	20
EBIT Margin	6.84%	6.88%	1.21%	-5.48%	9.52%	0.11%
Effective Tax Rate	38.16%	37.14%	21.10%	-	35.49%	122.32%

Updated May 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q